Obesity drugmaker Novo Nordisk misses Q2 profit forecast
Novo Nordisk has today trimmed its full-year profit outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, stirring worries among investors about stiffening competition from Eli Lilly.
Business
• 07 Aug 24
